Latest Breaking News On - Owen pearson - Page 2 : comparemela.com

4.6 (8) Kesimpta (ofatumumab) has been approved in the U.K. as the first self-administered, at-home, B-cell-targeting therapy for people with relapsing forms of multiple sclerosis (MS) and active disease. More specifically, the approval includes patients with either clinically isolated syndrome, relapsing-remitting MS (RRMS), or active secondary progressive MS (SPMS), who have been experiencing relapses or showing new lesions on MRI scans. This approval by the Medicines and Healthcare Products Regulatory Agency (MHRA) follows similar decisions in the E.U., the U.S., Canada, Switzerland, Singapore, Australia, Japan, Argentina, the United Arab Emirates, Albania, and India. The U.K.’s National Institute for Health Care and Excellence (NICE) and the Scottish Medicines Consortium now will decide whether to add Kesimpta to their respective National Health Service (NHS), which would allow patients to access treatments at low or no cost. NICE’s decision is

New yorkUnited statesUnited kingdomUnited arab emiratesColumbia universitySanofi genzymeDavid martinOwen pearsonChinmay bhattUniversity of lisbonDepartment of microbiology immunologyBiomedical sciencesNational health serviceUk national institute for health careHealthcare products regulatory agencyLaboratory of doctor davida fidock